<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan S Leventhal, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maja Mockenhaupt, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H195039099"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acneiform eruption is the prototypical cutaneous adverse reaction associated with all epidermal growth factor receptor (EGFR) inhibitors, which include monoclonal antibodies and oral small molecules used for the treatment of certain advanced or metastatic cancers, such as non-small cell lung cancer (<a class="drug drug_general" data-topicid="90144" href="/d/drug information/90144.html" rel="external">afatinib</a>, <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a>, <a class="drug drug_general" data-topicid="105441" href="/d/drug information/105441.html" rel="external">osimertinib</a>, <a class="drug drug_general" data-topicid="132715" href="/d/drug information/132715.html" rel="external">mobocertinib</a>, <a class="drug drug_general" data-topicid="105609" href="/d/drug information/105609.html" rel="external">necitumumab</a>, <a class="drug drug_general" data-topicid="131693" href="/d/drug information/131693.html" rel="external">amivantamab</a>), pancreatic cancer (erlotinib), breast cancer (<a class="drug drug_general" data-topicid="10093" href="/d/drug information/10093.html" rel="external">lapatinib</a>, <a class="drug drug_general" data-topicid="114008" href="/d/drug information/114008.html" rel="external">neratinib</a>), colon cancer (<a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a>, <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a>), and head and neck cancer (cetuximab). Acneiform eruption is also one of the most frequent adverse effects of inhibitors of the EGFR downstream mitogen-activated protein kinase kinase (MEK) signaling pathways MEK1 and MEK2 (eg, <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>, <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a>, <a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">binimetinib</a>, <a class="drug drug_general" data-topicid="127843" href="/d/drug information/127843.html" rel="external">selumetinib</a>), especially when used as monotherapy [<a href="#rid1">1-3</a>].</p><p>Although not life threatening, acneiform eruption affects cosmetically sensitive areas, causes pain and pruritus, and may impair the patient's quality of life and adherence to cancer therapies [<a href="#rid4">4</a>].</p><p>The acneiform eruption secondary to EGFR/MEK inhibitors will be reviewed in this topic. Other cutaneous adverse reactions to EGFR inhibitors and other molecularly targeted therapy or conventional chemotherapy agents are discussed separately. (See  <a class="medical medical_review" href="/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy"</a> and  <a class="medical medical_review" href="/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents"</a>.)</p><p class="headingAnchor" id="H195039106"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H4278184344"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>All-grade acneiform eruptions occur in up to 90 percent of patients treated with EGFR or MEK inhibitors, with approximately 10 to 20 percent of patients developing severe (grade 3 or 4) eruption  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>) [<a href="#rid1">1,2,5-7</a>]. Patients of any age may be affected [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H3800629511"><span class="h2">Risk factors for severe rash</span><span class="headingEndMark"> — </span>Potential risk factors for the development of severe EGFR inhibitor-related acneiform rash include age, sex, skin phototype, ultraviolet (UV) exposure, and combination with other treatment modalities (eg, conventional cytotoxic chemotherapy agents, radiotherapy) [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – In patients with advanced non-small cell lung cancer treated with <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, age ≥70 is associated with an increased risk of severe (grade ≥3  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>)) rash [<a href="#rid8">8,11</a>]. However, in a study of patients treated with <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> for metastatic colon cancer, age ≤70 and male sex were associated with a higher rate of grade 3 eruption [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin phototype</strong> – In a retrospective study of patients treated with <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, grade 3 to 4 rash  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>) occurred almost exclusively in patients with skin phototype I/II  (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 2</a>) [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex</strong> – A retrospective study of 67 patients revealed that males were more likely to discontinue EGFR inhibitors because of rash when compared with females [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sun exposure</strong> – The frequent localization of the acneiform eruption to sun-exposed areas, such as the face and the "V" area of the neck and upper chest, suggests that UV radiation may act as a cofactor in the development or severity of the skin eruption. However, in a randomized trial, the daily application of a sunscreen with a sun protection factor (SPF) of 60 did not prevent or reduce the severity of the skin reaction [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy</strong> – In a meta-analysis of nine trials (5333 patients), the incidence of grade ≥3 rash  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>) was higher in patients treated with <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> in combination with a variety of conventional cytotoxic agents than in patients treated with cetuximab alone [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking</strong> – Among patients with non-small cell lung cancer, smoking during therapy with <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> is associated with a lower incidence of skin eruption [<a href="#rid15">15</a>]. A possible mechanism is the induction of the liver cytochrome P450 3A4 with subsequent enhanced clearance of the drug [<a href="#rid15">15,16</a>]. This mechanism is supported by the observation that patients who are active smokers tolerate higher doses of erlotinib [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H195039113"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Direct inhibition of the EGFR and induction of an inflammatory response are critical steps in the development of the primary, papulopustular lesion [<a href="#rid17">17</a>]. However, the underlying molecular mechanisms are incompletely understood, as is the role of commensal skin microorganisms.</p><p class="headingAnchor" id="H195039120"><span class="h2">Direct receptor inhibition</span><span class="headingEndMark"> — </span>In the epidermis, the EGFR is preferentially expressed in undifferentiated, actively proliferating basal and suprabasal keratinocytes; outer layers of the hair follicle; and pilosebaceous glands [<a href="#rid18">18,19</a>]. Coupled to various intracellular signaling pathways, EGFR plays a critical role in maintaining epidermal homeostasis through regulation of keratinocyte proliferation, differentiation, migration, and survival [<a href="#rid20">20</a>]. The intracellular signaling pathways may include RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT), stress-activated protein kinase (SAPK), and Janus kinase/signal transducer and activator of transcription (JAK/STAT).</p><p>Direct receptor inhibition by tyrosine kinase inhibitors (TKIs) or monoclonal antibodies downregulates the level of the phosphorylated EGFR in basal and suprabasal keratinocytes and the outer layer of hair follicles, resulting in [<a href="#rid21">21-25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Diminished proliferation of basal keratinocytes, evidenced by the reduced expression of the proliferation marker Ki67 and increased expression of the negative growth regulator p27</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Growth arrest and apoptosis of keratinocytes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased expression of terminal differentiation markers keratin 1 and STAT3 in the basal keratinocytes, reflecting premature and accelerated differentiation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased migration of differentiating keratinocytes through the epidermis due to enhanced cell attachment, mediated by increased expression of desmoglein 2</p><p></p><p class="headingAnchor" id="H195039127"><span class="h2">Inflammatory response</span><span class="headingEndMark"> — </span>Exposure of epithelial cells to EGFR inhibitors induces upregulation of interleukin (IL) 1 and tumor necrosis factor (TNF)-alpha and increases synthesis of other inflammatory chemokines and cytokines (eg, monocyte chemoattractant protein 1 [CCL2], RANTES [CCL5], T lymphocyte-recruiting CCL18, CCL3, CCL27, and CXCL14) [<a href="#rid26">26</a>], resulting in the formation of an early infiltrate of CD45RO<sup>+</sup> T lymphocytes, Langerhans cells, macrophages, and TNF-related apoptosis-inducing ligand (TRAIL)-positive cells with dendritic morphology [<a href="#rid17">17,21,27,28</a>]. </p><p>Keratinocyte-derived cytokines appear to be the major force recruiting macrophages, mast cells, and granulocytes [<a href="#rid26">26</a>]. This hypothesis is supported by the finding that patients treated with <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> have elevated levels of serum CCL27 compared with normal controls [<a href="#rid26">26</a>]. The eventual influx of neutrophils contributes to the inflammation, manifesting as superficial perifolliculitis or suppurative folliculitis [<a href="#rid21">21,28</a>].</p><p>In addition, an increased number of total and highly degranulated mast cells has been demonstrated in lesional skin [<a href="#rid26">26</a>]. Macrophages may also play an important pathogenetic role, since in mouse models, their local depletion resulted in amelioration of cutaneous eruption [<a href="#rid29">29</a>].</p><p>The inflammatory response may also be secondary to altered growth and differentiation of follicular epithelium, which results in keratotic plugging, rupture of follicular infundibulum, and influx of neutrophils [<a href="#rid28">28</a>]. This theory is supported by the observation that abnormal pilosebaceous units are present in both affected and unaffected skin of patients exposed to EGFR inhibitors [<a href="#rid27">27</a>]. In mouse models, an initial alteration in hair follicles and pilosebaceous units is followed by inflammatory changes [<a href="#rid30">30,31</a>]. </p><p class="headingAnchor" id="H195039134"><span class="h2">Role of microorganisms</span><span class="headingEndMark"> — </span>In vitro investigations demonstrated the ability of <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> to inhibit the expression of human beta-defensin-3, cathelicidin LL37, and ribonuclease 7, which are critical components of the innate antimicrobial defense system. Furthermore, diminished expression of claudin-1, a tight junction protein, is significantly reduced in lesional skin of EGFR inhibitor-treated patients, which may contribute to the disruption of the epidermal barrier and increase the risk of cutaneous infections [<a href="#rid26">26</a>]. </p><p>In mouse models, it has been shown that when EGFR is inhibited or absent, the opening of the follicular ostia during hair eruption allows for the penetration of commensal microorganisms into the hair follicle, which initiates an inflammatory reaction [<a href="#rid32">32</a>]. A study using gene expression profiling of biopsy samples of lesional skin found that EGFR/MEK inhibitors interact with the commensal bacterium <em>Cutibacterium acnes</em> within the microbiome of pilosebaceous follicles to induce IL-36-gamma expression in keratinocytes and, subsequently, IL-8-mediated neutrophil recruitment and inflammation [<a href="#rid33">33</a>].</p><p>Colonization with <em>Staphylococcus aureus</em> may be seen early in the course of the cutaneous eruption [<a href="#rid26">26</a>]. Secondary infection with <em>S. aureus</em> may also have a role in the late phase of the rash, sometimes after several months of therapy [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H1389454619"><span class="h2">Role of ultraviolet radiation exposure</span><span class="headingEndMark"> — </span>The frequent localization of the acneiform eruption to sun-exposed areas, such as the face and the "V" area of the neck and upper chest, suggests that ultraviolet (UV) radiation may act as a cofactor in the development or severity of skin eruption. Preclinical data also implicate EGFR as an important mediator of keratinocyte proliferation and survival in response to exposure to UV radiation. Inhibition of EGFR in cultured keratinocytes prior to UV radiation exposure has been shown to decrease cell survival and enhance apoptosis/necrosis following UV irradiation compared with cells exposed only to UV radiation [<a href="#rid17">17,35</a>]. However, in a randomized trial, the daily application of a sunscreen with a sun protection factor (SPF) of 60 did not prevent or reduce the severity of the skin reaction [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H3612515"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>The most frequently affected structures include hair follicles (61 percent), epidermis (52 percent), and sebaceous glands (45 percent) [<a href="#rid27">27</a>]. The two major histopathologic patterns are a superficial perifolliculitis, characterized by neutrophilic infiltrate surrounding the hyperkeratotic and/or ectatic follicular infundibula, and a florid, neutrophilic, suppurative folliculitis with rupture of the epithelial lining [<a href="#rid36">36,37</a>].</p><p>The stratum corneum is compact and eosinophilic, and its normal, basket-weave appearance is lost [<a href="#rid22">22,38</a>]. Epidermal atrophy, keratinocyte dysmaturation, and dyskeratosis may be seen [<a href="#rid39">39</a>]. Other reported alterations include intraepidermal acantholysis, vacuolar degeneration of the basal cell layer, prominent keratin plugs, and lichenoid changes [<a href="#rid22">22,28</a>]. The sebaceous glands are hypoplastic, with poorly differentiated sebocytes and keratinocytes [<a href="#rid27">27</a>]. The histologic alterations of the pilosebaceous units without an inflammatory infiltrate can also be seen in uninvolved skin [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H195039141"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3104375009"><span class="h2">Clinical features and skin areas involved</span><span class="headingEndMark"> — </span>The primary lesion of the EGFR/MEK inhibitor-induced acneiform eruption is a folliculocentric, erythematous papule or pustule. Areas rich in sebaceous glands (eg, the scalp, face  (<a class="graphic graphic_picture graphicRef121768" href="/d/graphic/121768.html" rel="external">picture 1</a>), and particularly the nose, cheeks, nasolabial folds, and perioral region) are most commonly affected. The upper trunk and, especially, the "V" region of the neck and chest  (<a class="graphic graphic_picture graphicRef121769" href="/d/graphic/121769.html" rel="external">picture 2</a>) are also involved [<a href="#rid28">28,40</a>]. Less frequently, the eruption may extend to the lower trunk  (<a class="graphic graphic_picture graphicRef55753" href="/d/graphic/55753.html" rel="external">picture 3</a>), buttocks, and extremities. The palmoplantar surfaces are characteristically spared [<a href="#rid41">41</a>].</p><p>Pruritus, irritation, burning sensation, and skin pain are frequent associated symptoms [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H2095043354"><span class="h2">Timing of rash development</span><span class="headingEndMark"> — </span>The onset of the eruption typically occurs within the first two weeks of therapy, but it can occur up to two months after starting the treatment [<a href="#rid43">43,44</a>].</p><p>The acneiform eruption generally evolves through four distinct phases [<a href="#rid45">45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Week 1</strong> –<strong> </strong>Sensory disturbance (dysesthesia) accompanied by erythema and edema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weeks 1 to 3</strong> –<strong> </strong>Development of erythematous papules and pustules.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weeks 3 to 4</strong> –<strong> </strong>Formation of crusts from purulent material and necrotic keratinocytes/debris.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weeks 4 and later</strong> –<strong> </strong>Persistent erythema with scattered telangiectasias and skin dryness. Late-phase presentations may have purpura and punched-out ulcers, which favor the buttocks and legs [<a href="#rid46">46</a>].</p><p></p><p class="headingAnchor" id="H3369940032"><span class="h2">Clinical course</span><span class="headingEndMark"> — </span>The clinical course is characterized by waxing and waning of lesions. Partial or even complete resolution may be seen despite continued EGFR inhibitor therapy [<a href="#rid43">43,47,48</a>]. Following the discontinuation of the offending agent, resolution typically occurs in four weeks [<a href="#rid48">48,49</a>].</p><p class="headingAnchor" id="H1744212895"><span class="h1">RELATIONSHIP BETWEEN RASH AND SURVIVAL</span><span class="headingEndMark"> — </span>Several studies have noted an association between acneiform eruption and increased overall response rate or survival [<a href="#rid36">36,50-57</a>]. This suggests that the skin eruption may be a surrogate marker for efficacy of EGFR inhibitor therapy and that acneiform eruption is <strong>not</strong> a contraindication to continued EGFR inhibitor therapy. However, the strategy for dose escalation based upon the rash grade ("dosing to rash") requires further study before it can be routinely recommended.</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 24 trials (3312 patients) of <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> or <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a> for non-small cell lung cancer, patients who developed a rash had a lower risk of death (hazard ratio [HR] 0.30, 95% CI 0.21-0.43) and disease progression (HR 0.50, 95% CI 0.41-0.61) than patients without a rash [<a href="#rid58">58</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another meta-analysis of 14 trials with 1106 patients with advanced biliary cancer treated with EGFR inhibitors, higher grades of acneiform rash were associated with longer overall and progression-free survival (HR 0.47, 95% CI 0.31-0.71, and HR 0.51, 95% CI 0.36-0.72, respectively) compared with lower grades or no rash [<a href="#rid59">59</a>].</p><p></p><p>Similarly, patients with metastatic colorectal cancer with wild-type <em>KRAS </em>who developed moderate or severe rash when treated with <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a> or <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> had a significantly prolonged overall survival, progression-free survival, and overall response rate [<a href="#rid60">60</a>]. In addition, in a small, randomized trial, dose escalation of EGFR inhibitors in patients with grade ≤1 rash was associated with an increased response rate to treatment [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H699849676"><span class="h1">COMPLICATIONS AND SEQUELAE</span><span class="headingEndMark"> — </span>Acneiform eruption is rarely life threatening [<a href="#rid4">4</a>]. However, it affects cosmetically sensitive areas, causes pain and pruritus, and may impair the patient's quality of life and adherence to cancer therapies.</p><p class="headingAnchor" id="H699849684"><span class="h2">Secondary infection</span><span class="headingEndMark"> — </span>Although the initial pustules are sterile, secondary infection of the affected skin may occur [<a href="#rid28">28</a>]. A retrospective analysis of 221 patients treated with <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a>, <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a>, <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, or <a class="drug drug_general" data-topicid="10093" href="/d/drug information/10093.html" rel="external">lapatinib</a> found that 38 percent of patients developed infections from bacteria, dermatophytes, or viruses [<a href="#rid62">62</a>]. <em>S. aureus</em> was isolated from approximately 60 percent of infected lesions. Staphylococcal bacteremia has been reported in patients with severe skin toxicity induced by erlotinib [<a href="#rid63">63,64</a>]. A 2014 meta-analysis of 26 randomized trials (14,066 patients) reported an increased risk for severe infections in patients treated with anti-EGFR monoclonal antibodies (relative risk 1.34, 95% CI 1.10-1.62) [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H699849441"><span class="h2">Cutaneous sequelae</span><span class="headingEndMark"> — </span>Long-term, cutaneous sequelae of EGFR inhibitor-induced acneiform rash include postinflammatory hyperpigmentation, telangiectasias, and erythema [<a href="#rid66">66,67</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postinflammatory hyperpigmentation</strong> − Postinflammatory hyperpigmentation is typically a late adverse event, manifesting after several months of treatment. It occurs most often in patients with darkly pigmented skin  (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 2</a>) and can be exacerbated by excessive ultraviolet (UV) radiation exposure [<a href="#rid67">67</a>]. Topical <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> 4% cream may be used in an attempt to reduce the hyperpigmentation [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Telangiectasias and erythema</strong> – Dilated, superficial capillaries and erythema may be observed in areas previously affected by the acneiform eruption one to two months after treatment. The initiating event in the development of telangiectasias could be the loss of structural support secondary to connective tissue destruction or the proliferation of endothelial cells in areas of keratinocyte necrosis that are present in follicular pustules [<a href="#rid17">17</a>]. Pulsed dye laser therapy may be used to reduce the redness [<a href="#rid68">68</a>].</p><p></p><p class="headingAnchor" id="H699849637"><span class="h2">Impact on patients' quality of life</span><span class="headingEndMark"> — </span>Symptoms such as pain, pruritus, burning, and irritation are observed in approximately 60 percent of patients with EGFR inhibitor-induced acneiform eruption and can negatively affect the quality of life [<a href="#rid49">49,69</a>]. A retrospective study examined the data from 67 patients who had completed the Skindex-16 (a self-reported, dermatology-specific, quality-of-life questionnaire) at the time of their initial visit for skin reaction to EGFR inhibitors [<a href="#rid42">42</a>]. A positive correlation was found between rash severity and median scores for symptoms, emotions, and function, with the highest score reported for the emotions domain.</p><p class="headingAnchor" id="H195039162"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of acneiform eruption in patients receiving EGFR inhibitor therapy is usually straightforward and clinical, based upon the morphology and distribution of the rash (eg, erythematous, follicular papules and pustules in areas rich in sebaceous glands)  (<a class="graphic graphic_picture graphicRef55753" href="/d/graphic/55753.html" rel="external">picture 3</a>).</p><p>A skin biopsy is not routinely performed in clinical practice and is generally not needed for the diagnosis. However, if the clinical presentation is atypical or the eruption does not respond to treatment, a skin biopsy may be performed for accurate diagnosis.</p><p>If viral or bacterial superinfection is suspected based on the morphology of lesions (eg, yellow crusts or discharge, no response to treatment, painful skin lesions, peripheral erythema) or worsening of the initial eruption, cultures of exudates should be obtained. A potassium hydroxide (KOH) preparation may be useful to exclude <em>Pityrosporum</em> folliculitis or tinea barbae. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H195039171"><span class="h1">GRADING OF SEVERITY</span><span class="headingEndMark"> — </span>Although not always performed in clinical practice, grading the severity of the acneiform eruption is important in guiding the approach to management  (<a class="graphic graphic_algorithm graphicRef87010" href="/d/graphic/87010.html" rel="external">algorithm 1</a>). In clinical trials and in some oncology practices, the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) is the most commonly employed scale to assess the severity of cutaneous adverse reactions to cancer treatment  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>) [<a href="#rid70">70,71</a>]. However, the CTCAE scale, which is based upon the body surface area involvement and symptoms, may not capture specific features of the acneiform rash (eg, involvement of cosmetically sensitive areas, subacute/chronic course) and does not incorporate the patient's perception of severity [<a href="#rid72">72,73</a>].</p><p class="headingAnchor" id="H195039178"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of EGFR inhibitor-induced acneiform eruption includes acneiform eruptions induced by other drugs and other uncommon, papulopustular eruptions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced acne</strong> – Drug-induced acne typically presents with a monomorphous, inflammatory, papular eruption involving the trunk  (<a class="graphic graphic_picture graphicRef86995" href="/d/graphic/86995.html" rel="external">picture 4</a>). Medications associated with drug-induced acne are listed in the table  (<a class="graphic graphic_table graphicRef76762" href="/d/graphic/76762.html" rel="external">table 3</a>) [<a href="#rid74">74</a>]. Other anticancer agents that may also be associated with an acneiform eruption include [<a href="#rid75">75-78</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inhibitors of mammalian target of rapamycin (mTOR), such as <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multikinase inhibitors, such as <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>, and <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> (see  <a class="medical medical_review" href="/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Pityrosporum</em></strong><strong> folliculitis</strong> – <em>Pityrosporum</em> folliculitis is a skin infection caused by yeasts of the genus <em>Malassezia</em> and characterized by a monomorphous eruption of papules and pustules on the upper trunk or arms  (<a class="graphic graphic_picture graphicRef86998 graphicRef86997" href="/d/graphic/86998.html" rel="external">picture 5A-B</a>). Characteristic budding yeasts are detected on histologic examination of a skin biopsy after treatment with potassium hydroxide (KOH). (See  <a class="medical medical_review" href="/d/html/2428.html" rel="external">"Invasive Malassezia infections", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tinea barbae</strong> – Tinea (sycosis) barbae is a skin infection caused by dermatophytes of the genus <em>Trichophyton</em>, occurring predominantly in males. The superficial type presents with papules and pustules in the beard and mustache area  (<a class="graphic graphic_picture graphicRef86999 graphicRef87000" href="/d/graphic/86999.html" rel="external">picture 6A-B</a>). A KOH preparation shows the segmented hyphae and arthrospores characteristic of dermatophyte infections  (<a class="graphic graphic_picture graphicRef60102" href="/d/graphic/60102.html" rel="external">picture 7</a>). (See  <a class="medical medical_review" href="/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilic folliculitis</strong> – Eosinophilic folliculitis is a pruritic eruption most commonly occurring in patients with HIV and presenting with recurrent crops of follicular papules and pustules predominantly involving the head, neck, and upper trunk  (<a class="graphic graphic_picture graphicRef54404 graphicRef87125" href="/d/graphic/54404.html" rel="external">picture 8A-B</a>). Peripheral eosinophilia is often present. Histology reveals infiltration of eosinophils into hair follicles and perifollicular areas  (<a class="graphic graphic_picture graphicRef78005 graphicRef67192" href="/d/graphic/78005.html" rel="external">picture 9A-B</a>). (See  <a class="medical medical_review" href="/d/html/4032.html" rel="external">"HIV-associated eosinophilic folliculitis"</a>.)</p><p></p><p class="headingAnchor" id="H637929210"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H4252670335"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Before initiating treatment with EGFR inhibitors, patients should be educated about adopting general skin care measures, which include [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding frequent washing with hot water (hand washing, shower, baths).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding antibacterial or perfumed soaps and detergents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding the use of skin irritants, such as over-the-counter antiacne medications, solvents, or disinfectants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding excessive sun exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regularly using a broad-spectrum ultraviolet A/ultraviolet B (UVA/UVB) sunscreen with a sun protection factor (SPF) ≥15 with inorganic ingredients (<a class="drug drug_general" data-topicid="10326" href="/d/drug information/10326.html" rel="external">zinc oxide</a>, titanium dioxide). Sunscreens should be applied to exposed areas of the body every two hours when outside.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Using thick, alcohol-free moisturizers (creams or ointments) twice daily.</p><p></p><p class="headingAnchor" id="H1382984530"><span class="h2">Preemptive therapy</span><span class="headingEndMark"> — </span>We suggest prophylactic oral antibiotics in conjunction with topical corticosteroids for patients initiating treatment with EGFR inhibitors. Treatment is started on the same day as EGFR inhibitor therapy and continued for six weeks. We typically use <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg twice a day, <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> 100 mg daily, or oxytetracycline 500 mg twice daily for six weeks [<a href="#rid7">7</a>]. Alternative antibiotics include cephalosporins (eg, <a class="drug drug_general" data-topicid="9212" href="/d/drug information/9212.html" rel="external">cefadroxil</a> 500 mg twice daily) or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (160 mg/800 mg twice daily).</p><p>A low-potency topical corticosteroid (eg, <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> 2.5%, <a class="drug drug_general" data-topicid="9399" href="/d/drug information/9399.html" rel="external">alclometasone</a> 0.05% cream  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 4</a>)) is applied twice daily to the face and chest.</p><p>The efficacy of oral tetracyclines for the prevention of the acneiform eruption has been evaluated in several randomized and nonrandomized studies and in two meta-analyses [<a href="#rid79">79-81</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 2012 meta-analysis of four randomized trials including 351 patients [<a href="#rid82">82-85</a>], patients who initiated prophylactic treatment with a <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> on the same day as or the day before initiating EGFR inhibitor therapy had a decreased incidence of moderate to severe (grade ≥2  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>)) folliculitis (combined odds ratio [OR] 0.19, 95% CI 0.12-0.31) [<a href="#rid79">79</a>]. However, the benefit was lost after discontinuation of treatment. The incidence of mild (grade 1  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>)) folliculitis was not changed by prophylactic tetracyclines. The data were insufficient to determine the optimal treatment regimen and duration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent 2016 meta-analysis including nine randomized trials and four observational studies (1073 patients) confirmed the benefit of preemptive antibiotic therapy for the prevention of the acneiform eruption [<a href="#rid80">80</a>]. In this meta-analysis, prophylactic treatment with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> reduced the risk of developing a skin rash of any grade by approximately 50 percent (OR 0.54, 95% CI 0.40-0.73) and reduced the risk of grade 2 or 3 rash by approximately 70 percent (OR 0.36, 95% CI 0.22-0.60). The results were similar when the analysis was restricted to randomized trials.</p><p></p><p>There are a few studies evaluating the efficacy of topical treatments alone or in conjunction with oral antibiotics for the prevention of acneiform eruption:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tazarotene</strong> – In a randomized trial of 48 patients initiating <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> therapy with or without prophylactic <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9665" href="/d/drug information/9665.html" rel="external">tazarotene</a> 0.05% cream applied to one side of the face was not effective in preventing the acneiform eruption when used as a single agent and provided little benefit beyond that seen with minocycline alone when used in combination with oral minocycline [<a href="#rid82">82</a>]. In addition, tazarotene was associated with significant skin irritation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical vitamin K1</strong> – In a randomized trial including 126 colon cancer patients initiating <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> therapy, vitamin K1 cream given in combination with oral <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> was not effective in preventing the acneiform eruption compared with doxycycline and vehicle [<a href="#rid86">86</a>]. Grade 2 to 4 acneiform rash (defined according to the Common Terminology Criteria for Adverse Events [CTCAE] v.4.02) occurred in 73 percent of patients in the vitamin K1 group and 64 percent of those in the vehicle group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>dapsone</strong><strong> 5% gel</strong> – In a small,<strong> </strong>randomized,<strong> </strong>split-face/chest study of 11 patients, <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> 5% gel applied twice daily was associated with a nonstatistically significant reduction in lesion count compared with a moisturizer [<a href="#rid87">87</a>]. All patients were also treated with <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> 100 mg daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>doxycycline</strong> – In a small, phase II trial, 24 patients with metastatic colorectal cancer applied topical <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 4% foam twice daily on one side of the face and vehicle foam on the other side before the initiation of EGFR inhibitor therapy [<a href="#rid88">88</a>]. Grade 2 or 3 rash occurred less frequently on the sides treated with topical doxycycline compared with the sides treated with vehicle. Topical treatment was well tolerated, with mild, local reaction reported in five patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>erythromycin</strong><strong> 2% ointment</strong> – In a randomized trial, 88 patients with colorectal cancer receiving <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a> were treated with either <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg twice daily or <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> ointment 2% followed by doxycycline in case of insufficient activity [<a href="#rid89">89</a>]. More patients treated with prophylactic erythromycin 2% ointment developed moderate or severe skin toxicity, as measured with the WoMo (Wollenberg and Moosmann) score [<a href="#rid90">90</a>], at an earlier time compared with those treated with doxycycline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>chloramphenicol</strong> – A single-center, randomized trial investigated the efficacy of <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> 3%/<a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> 0.05% ointment and chloramphenicol 3% ointment alone versus placebo (aqua cream) in preventing the acneiform eruption from EGFR inhibitors [<a href="#rid91">91</a>]. At 14 and 30 days, there was no difference among groups in the primary endpoint (proportion of patients developing grade ≥3 rash). However, at 30 days, fewer patients in the chloramphenicol groups than in the placebo group had &gt;10 papulopustular lesions (6, 16, and 43 percent, respectively).</p><p></p><p class="headingAnchor" id="H195039192"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H29755924"><span class="h2">General principles</span><span class="headingEndMark"> — </span>The management of the acneiform eruption should be individualized for each patient, based upon the type, severity, and location of the lesions. In most cases, acneiform eruption is <strong>not</strong> a contraindication to continued EGFR inhibitor therapy. In intolerable or severe cases, dose modification or interruption of a potentially life-prolonging therapy may be necessary [<a href="#rid92">92</a>]. However, clinicians should take into consideration the patient's willingness to continue treatment despite a severe cutaneous reaction [<a href="#rid93">93</a>]. </p><p>Management in consultation with a dermatologist is suggested in the following situations:</p><p class="bulletIndent1"><span class="glyph">●</span>The skin reaction does not improve within two weeks of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The eruption is severe (grade 3 to 4  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>)).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The eruption has an atypical appearance or distribution. (See <a class="local">'Clinical manifestations'</a> above.) </p><p></p><p>Randomized trials have shown benefit with topical corticosteroids, topical and systemic antibiotics, and oral <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid45">45,94</a>]. Prophylactic therapy is recommended for all patients  (<a class="graphic graphic_algorithm graphicRef87010" href="/d/graphic/87010.html" rel="external">algorithm 1</a>). Grading the severity of rash is discussed above. (See <a class="local">'Grading of severity'</a> above.)</p><p class="headingAnchor" id="H699849803"><span class="h2">Treatment of pruritus</span><span class="headingEndMark"> — </span>Oral H1 antihistamines, including sedating (eg, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, <a class="drug drug_general" data-topicid="8544" href="/d/drug information/8544.html" rel="external">hydroxyzine</a>, <a class="drug drug_general" data-topicid="9390" href="/d/drug information/9390.html" rel="external">doxepin</a>) or nonsedating (eg, <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a>, <a class="drug drug_general" data-topicid="8445" href="/d/drug information/8445.html" rel="external">fexofenadine</a>, <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a>) agents, may be beneficial for patients with pruritus [<a href="#rid49">49,95</a>]. In a clinical trial, <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a> (a neurokinin 1 [NK1] receptor antagonist) was effective in reducing pruritus intensity by &gt;80 percent in 41 of 45 patients treated with EGFR inhibitors and tyrosine kinase inhibitors (TKIs) [<a href="#rid96">96</a>]. Pruritus did not recur in 87 percent of patients during the 90-day study period. However, aprepitant should be used with caution in patients receiving <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, since aprepitant-induced inhibition of the liver cytochrome P450 3A4 may increase the trough levels of erlotinib [<a href="#rid97">97</a>].</p><p>Gamma-aminobutyric acid (GABA) agonists, such as <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>, may be tried if oral antihistamines are ineffective. Evidence of benefit in patients with acneiform eruption secondary to EGFR inhibitors is limited [<a href="#rid98">98</a>], but they are used to treat other forms of chronic pruritus. (See  <a class="medical medical_review" href="/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus"</a>.)</p><p class="headingAnchor" id="H29755685"><span class="h2">Patients with grade 1 rash</span><span class="headingEndMark"> — </span>For patients with grade 1 rash  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>), we suggest topical corticosteroids and topical antibiotics  (<a class="graphic graphic_algorithm graphicRef87010" href="/d/graphic/87010.html" rel="external">algorithm 1</a>). We typically use low-potency topical corticosteroids (groups 6 and 7  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 4</a>)) plus <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> 1% or <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> 5% gel twice a day for at least four weeks.</p><p>We generally reassess patients after four weeks of treatment. If the acneiform eruption has not improved or has worsened, patients are treated in the same way as those with grade 2 rash.</p><p class="headingAnchor" id="H29755709"><span class="h2">Patients with grade 2 rash</span><span class="headingEndMark"> — </span>For patients with grade 2 rash  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>), we suggest topical corticosteroids and oral <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> antibiotics  (<a class="graphic graphic_algorithm graphicRef87010" href="/d/graphic/87010.html" rel="external">algorithm 1</a>). We use low-potency topical corticosteroids (group 6  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 4</a>)) twice a day on the face and neck and <a class="drug drug_general" data-topicid="8460" href="/d/drug information/8460.html" rel="external">fluocinonide</a> 0.05% cream twice a day on the chest and back for at least four weeks and either <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg or <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> 100 mg twice per day for four to six weeks.</p><p>If a patient with grade 2 rash is already on an oral <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, an alternative antibiotic, such as a first-generation oral cephalosporin (eg, <a class="drug drug_general" data-topicid="9231" href="/d/drug information/9231.html" rel="external">cephalexin</a> 500 mg twice per day, <a class="drug drug_general" data-topicid="9212" href="/d/drug information/9212.html" rel="external">cefadroxil</a> 500 mg twice per day) or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (<a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a> 160 mg/sulfamethoxazole 800 mg twice per day), can be given for four weeks. For pediatric patients under age 8, we recommend a first-generation oral cephalosporin or <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> 500 mg twice daily instead of an oral tetracycline [<a href="#rid99">99</a>].</p><p>If viral or bacterial superinfection is suspected based on the morphology of lesions (eg, yellow crusts or discharge, no response to antibiotics, painful skin lesions, peripheral erythema), degree of suppurative exudate, or worsening of the initial eruption, cultures of exudates should be obtained to determine appropriate antimicrobial therapy.</p><p>We generally reassess patients after two weeks of treatment. If no improvement or worsening is noted after two weeks of treatment, patients are treated in the same way as those with grade ≥3 rash.</p><p class="headingAnchor" id="H662500"><span class="h2">Patients with grade ≥3 rash</span><span class="headingEndMark"> — </span>In patients with grade ≥3 rash, intolerable grade 2 rash, or rash that interferes with self-care activities of daily living or impairs the quality of life  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>), dose modification as per prescribing information or interruption is warranted  (<a class="graphic graphic_algorithm graphicRef87010" href="/d/graphic/87010.html" rel="external">algorithm 1</a>).</p><p>Decisions regarding interruption or even discontinuation of EGFR inhibitor therapy must involve the patient, the patient's oncologist, and the patient's dermatologist. The potential risks and benefits and the patient's values and preferences must be considered. Treatment may be reinitiated after toxicity has resolved to baseline or grade ≤1, according to the instructions provided in the prescribing information for the particular agent [<a href="#rid45">45,94</a>].</p><p>In addition to interruption or discontinuation of EGFR inhibitor therapy, we suggest treatment with oral antibiotics plus a short course of systemic corticosteroids:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg or <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> 100 mg is given twice a day for at least four weeks. First-generation oral cephalosporins (eg, <a class="drug drug_general" data-topicid="9231" href="/d/drug information/9231.html" rel="external">cephalexin</a> 500 mg twice per day, <a class="drug drug_general" data-topicid="9212" href="/d/drug information/9212.html" rel="external">cefadroxil</a> 500 mg twice per day) or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (<a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a> 160 mg/sulfamethoxazole 800 mg/twice per day) given for four weeks can be used as alternatives when patients do not benefit from <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> antibiotics or have a culture-proven infection with organisms resistant to tetracycline antibiotics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg up to a maximum of 40 mg per day is given for seven days.</p><p></p><p>Improvement should be noted within two weeks. If a viral or bacterial superinfection is suspected, cultures of exudates should be obtained prior to the initiation of the antibiotic treatment to determine appropriate antimicrobial therapy. </p><p>Oral corticosteroids for the treatment of severe acneiform eruption have not been evaluated in randomized trials, and their use is based upon their anti-inflammatory properties and clinical experience.</p><p class="headingAnchor" id="H27163434"><span class="h2">Refractory grade ≥3 rash</span><span class="headingEndMark"> — </span>For patients with grade ≥3 rash that does not improve in two weeks with dose modification or interruption and the regimen of oral antibiotics plus systemic corticosteroids described above, low-dose <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a> (20 to 30 mg per day) or <a class="drug drug_general" data-topicid="9250" href="/d/drug information/9250.html" rel="external">acitretin</a> (10 to 25 mg a day) may be tried [<a href="#rid100">100</a>].</p><p>Oral tetracyclines are discontinued before initiating oral <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a>. Improvement is generally evident within four weeks [<a href="#rid101">101</a>]. Therapy is continued for at least two months after patients resume EGFR inhibitor at regular dose.</p><p>The evidence for efficacy of oral <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a> for severe acneiform eruption is limited to single case reports and small case series [<a href="#rid101">101-105</a>]. Indirect evidence of efficacy is derived from studies of the treatment of acne vulgaris. (See  <a class="medical medical_review" href="/d/html/129467.html" rel="external">"Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Oral isotretinoin'</a>.)</p><p>In a retrospective chart review, nine patients treated with EGFR or MEK inhibitors with or without immunotherapy who developed an acneiform eruption were treated with <a class="drug drug_general" data-topicid="9250" href="/d/drug information/9250.html" rel="external">acitretin</a> or <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid106">106</a>]. Improvement was evident within one month, and the rash remained stable at grade 1 or less without a need for dose modification of cancer therapy. Improvement of pruritus and pain was also noted following initiation of oral retinoids.</p><p><a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">Isotretinoin</a> may aggravate some EGFR inhibitor adverse effects, such as skin dryness, cheilitis, or photosensitivity. Skin dryness and cheilitis can be alleviated by the application of alcohol-free emollients multiple times per day. Patients with increased photosensitivity should adopt sun protection measures, which include limiting the exposure to the sun, wearing protective clothing, and regular use of sunscreens with a sun protection factor (SPF) ≥30. (See  <a class="medical medical_review" href="/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Mucocutaneous'</a>.)</p><p class="headingAnchor" id="H3559493918"><span class="h1">EXPERIMENTAL TREATMENTS</span></p><p class="headingAnchor" id="H2081558869"><span class="h2">Topical recombinant epidermal growth factor</span><span class="headingEndMark"> — </span>Two small studies have evaluated the efficacy of an ointment containing recombinant epidermal growth factor (EGF) [<a href="#rid107">107,108</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label study, 46 patients with grade ≥2 erlotinib-related skin effects (ERSE) were treated twice daily with an EGF ointment containing 1 part per million (ppm) of nepidermin [<a href="#rid108">108</a>]. At eight weeks, the overall response rate was 78 percent, with 31 patients (67 percent) having grade 2, 3, or 4 ERSE downgraded to grade ≤1 and 5 patients (11 percent) having grade 3 or 4 ERSE downgraded to grade 2 and lasting for at least two weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 80 patients with grade ≥2 ERSE received EGF ointment at a concentration of 1 ppm, 20 ppm, or placebo twice daily [<a href="#rid107">107</a>]. Response was defined as reduction of ERSE from grade ≥2 to grade ≤1 or grade ≥3 ERSE downgrading to grade 2 and lasting for at least two weeks. The response rate was 61.5 percent (95% CI 40.6-79.8 percent) in the 1 ppm group, 77.8 percent (95% CI 57.7-91.4 percent) in the 20 ppm group, and 44.4 percent (95% CI 25.5-64.7 percent) in the placebo group. Adverse events related to EGF treatment occurred in three patients (skin fissure, pyogenic granuloma, and periungual overgrowth).</p><p></p><p class="headingAnchor" id="H820691890"><span class="h2">Topical BRAF inhibitors</span><span class="headingEndMark"> — </span>Based on the observation that the incidence of acneiform eruption is lower in patients treated with EGFR inhibitors in combination with BRAF inhibitors, a four-week, phase I trial investigated the efficacy of a topical BRAF inhibitor in 10 patients treated with <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a> for metastatic colorectal cancer who developed grade 1 or 2 rash [<a href="#rid109">109</a>]. Six patients with grade 2 rash improved to grade 1, two patients remained stable, and two worsened.</p><p class="headingAnchor" id="H1796944457"><span class="h2">Topical polydatin</span><span class="headingEndMark"> — </span>A pilot study evaluated the efficacy of topical polydatin, a natural precursor of resveratrol, as adjunctive therapy to oral <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> 100 mg/day for the treatment and prevention of acneiform eruption [<a href="#rid110">110</a>]. In 20 patients with acneiform eruption, polydatin 1.5% cream applied twice daily resulted in a decrease of the eruption's grade according to the Common Terminology Criteria for Adverse Events (CTCAE) compared with baseline. Prophylactic treatment with polydatin 0.8% cream twice daily prevented the development of acneiform eruption through 24 weeks in all 20 patients who were symptom free at baseline. However, the benefit of topical polydatin for acneiform eruption should be confirmed in a randomized trial.</p><p class="headingAnchor" id="H195039241"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> − The acneiform (papulopustular) eruption is the prototypical cutaneous adverse reaction to treatment with epidermal growth factor receptor (EGFR) and mitogen-activated protein kinase kinase (MEK) inhibitors. It occurs in over 80 percent of patients and may be more frequent in older patients and in patients with lightly pigmented skin (phototypes I to III  (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 2</a>)). (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> − The eruption develops mainly in areas rich in sebaceous glands (eg, scalp, face, upper trunk) within the first two weeks of therapy  (<a class="graphic graphic_picture graphicRef55753" href="/d/graphic/55753.html" rel="external">picture 3</a>). Erythematous papules and pustules evolve to crusted lesions and eventually resolve, leaving persistent erythema, telangiectasias, and skin dryness. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> − The diagnosis of acneiform eruption in patients receiving EGFR inhibitor therapy is usually straightforward, based upon the morphology and distribution of the skin lesions (eg, erythematous and follicular papules or pustules in areas rich in sebaceous glands with sparing of palmoplantar surfaces)  (<a class="graphic graphic_picture graphicRef55753" href="/d/graphic/55753.html" rel="external">picture 3</a>). The severity is graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> − We suggest a prophylactic oral <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> in conjunction with topical corticosteroids for patients initiating treatment with EGFR inhibitors (<a class="grade" href="https://medilib.ir/uptodate/show/grade_4" rel="external">Grade 2A</a>). Treatment is started on the same day as EGFR inhibitor therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We typically use <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg twice a day or <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> 100 mg daily for six to eight weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low-potency corticosteroids  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 4</a>), such as <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> 2.5% or <a class="drug drug_general" data-topicid="9399" href="/d/drug information/9399.html" rel="external">alclometasone</a> 0.05% cream, are applied twice a day. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong>  (<a class="graphic graphic_algorithm graphicRef87010" href="/d/graphic/87010.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Grade 1 rash</strong> − For patients with grade 1 rash  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>) who have not initiated prophylactic therapy, we suggest topical corticosteroids with or without topical antibiotics (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We use low-potency topical corticosteroids (group 6  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 4</a>)) twice a day for four weeks and <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> 1% gel twice a day for four weeks. (See <a class="local">'Patients with grade 1 rash'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Grade 2 rash</strong> − For patients with grade 2 rash  (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 1</a>) who are not taking prophylactic <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, we suggest topical corticosteroids and oral tetracycline antibiotics  (<a class="graphic graphic_algorithm graphicRef87010" href="/d/graphic/87010.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We use low-potency topical corticosteroids (group 6  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 4</a>)) twice a day for four weeks and either <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg or <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> 100 mg orally twice a day for four weeks. First-generation oral cephalosporins (eg, <a class="drug drug_general" data-topicid="9231" href="/d/drug information/9231.html" rel="external">cephalexin</a>, <a class="drug drug_general" data-topicid="9212" href="/d/drug information/9212.html" rel="external">cefadroxil</a>) or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> can be used as alternative antibiotics for patients who are taking prophylactic tetracyclines or do not benefit from tetracyclines as well as for pediatric patients under age 8. (See <a class="local">'Patients with grade 2 rash'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Grade ≥3 rash</strong> − For patients with grade ≥3 rash who are not taking a prophylactic <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, we suggest treatment with an oral tetracycline plus a short course of systemic corticosteroids in addition to EGFR or MEK inhibitor dose modification or interruption (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We use either <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg or <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> 100 mg orally twice a day for at least four weeks and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg orally once per day for seven days.</p><p></p><p class="bulletIndent2">A first-generation oral cephalosporin (eg, <a class="drug drug_general" data-topicid="9231" href="/d/drug information/9231.html" rel="external">cephalexin</a>, <a class="drug drug_general" data-topicid="9212" href="/d/drug information/9212.html" rel="external">cefadroxil</a>) or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> can be used as alternative antibiotics for patients who are taking a prophylactic <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> or do not benefit from tetracyclines. Tetracyclines should be discontinued. (See <a class="local">'Patients with grade ≥3 rash'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory grade ≥3 rash</strong> − Low-dose <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a> (20 to 30 mg per day) or <a class="drug drug_general" data-topicid="9250" href="/d/drug information/9250.html" rel="external">acitretin</a> (10 to 25 mg a day) may be tried for patients with grade ≥3 rash that does not improve within two weeks with dose modification or interruption and the regimen of oral antibiotics plus systemic corticosteroids. Oral tetracyclines are discontinued before initiating oral isotretinoin. (See <a class="local">'Refractory grade ≥3 rash'</a> above.)</p><p></p><p class="headingAnchor" id="H4046856411"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Yevgeniy Balagula, MD, and Mario E Lacouture, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Anforth R, Liu M, Nguyen B, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol 2014; 55:250.</a></li><li><a class="nounderline abstract_t">Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:773.</a></li><li><a class="nounderline abstract_t">Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol 2014; 11:385.</a></li><li><a class="nounderline abstract_t">Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008; 13:1201.</a></li><li><a class="nounderline abstract_t">Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10:345.</a></li><li><a class="nounderline abstract_t">Bendell JC, Javle M, Bekaii-Saab TS, et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer 2017; 116:575.</a></li><li><a class="nounderline abstract_t">Lacouture ME, Sibaud V, Gerber PA, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆. Ann Oncol 2021; 32:157.</a></li><li><a class="nounderline abstract_t">Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26:2350.</a></li><li><a class="nounderline abstract_t">Jatoi A, Green EM, Rowland KM Jr, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009; 77:120.</a></li><li><a class="nounderline abstract_t">Balagula Y, Wu S, Su X, Lacouture ME. The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Ann Oncol 2011; 22:2366.</a></li><li><a class="nounderline abstract_t">Bigot F, Boudou-Rouquette P, Arrondeau J, et al. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. Invest New Drugs 2017; 35:242.</a></li><li><a class="nounderline abstract_t">Luu M, Boone SL, Patel J, et al. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. Clin Exp Dermatol 2011; 36:733.</a></li><li><a class="nounderline abstract_t">Takahashi H, Asaka J, Tairabune T, et al. Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance. J Clin Pharm Ther 2021; 46:1404.</a></li><li><a class="nounderline abstract_t">Jatoi A, Thrower A, Sloan JA, et al. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 2010; 15:1016.</a></li><li><a class="nounderline abstract_t">Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12:2166.</a></li><li><a class="nounderline abstract_t">Hughes AN, O'Brien ME, Petty WJ, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009; 27:1220.</a></li><li><a class="nounderline abstract_t">Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803.</a></li><li><a class="nounderline abstract_t">Nanney LB, Stoscheck CM, King LE Jr, et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990; 94:742.</a></li><li><a class="nounderline abstract_t">Nanney LB, Magid M, Stoscheck CM, King LE Jr. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984; 83:385.</a></li><li><a class="nounderline abstract_t">Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787.</a></li><li><a class="nounderline abstract_t">Han SS, Lee M, Park GH, et al. Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. Br J Dermatol 2010; 162:371.</a></li><li><a class="nounderline abstract_t">Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110.</a></li><li><a class="nounderline abstract_t">Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292.</a></li><li><a class="nounderline abstract_t">Rodeck U, Jost M, Kari C, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci 1997; 110 ( Pt 2):113.</a></li><li><a class="nounderline abstract_t">Lorch JH, Klessner J, Park JK, et al. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem 2004; 279:37191.</a></li><li><a class="nounderline abstract_t">Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 2013; 5:199ra111.</a></li><li><a class="nounderline abstract_t">Guttman-Yassky E, Mita A, De Jonge M, et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010; 46:2010.</a></li><li><a class="nounderline abstract_t">Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169.</a></li><li><a class="nounderline abstract_t">Mascia F, Lam G, Keith C, et al. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl Med 2013; 5:199ra110.</a></li><li><a class="nounderline abstract_t">Murillas R, Larcher F, Conti CJ, et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14:5216.</a></li><li><a class="nounderline abstract_t">Surguladze D, Deevi D, Claros N, et al. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res 2009; 69:5643.</a></li><li><a class="nounderline abstract_t">Klufa J, Bauer T, Hanson B, et al. Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy. Sci Transl Med 2019; 11.</a></li><li><a class="nounderline abstract_t">Satoh TK, Mellett M, Meier-Schiesser B, et al. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest 2020; 130:1417.</a></li><li><a class="nounderline abstract_t">Amitay-Laish I, David M, Stemmer SM. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Oncologist 2010; 15:1002.</a></li><li><a class="nounderline abstract_t">Peus D, Vasa RA, Meves A, et al. UVB-induced epidermal growth factor receptor phosphorylation is critical for downstream signaling and keratinocyte survival. Photochem Photobiol 2000; 72:135.</a></li><li><a class="nounderline abstract_t">Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55:657.</a></li><li><a class="nounderline abstract_t">Brodell LA, Hepper D, Lind A, et al. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors. J Cutan Pathol 2013; 40:865.</a></li><li><a class="nounderline abstract_t">Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003; 9:2478.</a></li><li><a class="nounderline abstract_t">Nardone B, Nicholson K, Newman M, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res 2010; 16:4452.</a></li><li><a class="nounderline abstract_t">Roé E, García Muret MP, Marcuello E, et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006; 55:429.</a></li><li><a class="nounderline abstract_t">Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007; 56:317.</a></li><li><a class="nounderline abstract_t">Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010; 116:3916.</a></li><li><a class="nounderline abstract_t">Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151:238.</a></li><li><a class="nounderline abstract_t">de Noronha e Menezes NM, Lima R, Moreira A, et al. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients. Eur J Dermatol 2009; 19:248.</a></li><li><a class="nounderline abstract_t">Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12:610.</a></li><li><a class="nounderline abstract_t">Tohyama M, Hamada M, Harada D, et al. Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash. J Dermatol 2020; 47:121.</a></li><li><a class="nounderline abstract_t">Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201.</a></li><li><a class="nounderline abstract_t">Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267.</a></li><li><a class="nounderline abstract_t">Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4:107.</a></li><li><a class="nounderline abstract_t">Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337.</a></li><li><a class="nounderline abstract_t">Fiala O, Pesek M, Finek J, et al. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Neoplasma 2013; 60:26.</a></li><li><a class="nounderline abstract_t">Stintzing S, Kapaun C, Laubender RP, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 2013; 132:236.</a></li><li><a class="nounderline abstract_t">Holch JW, Held S, Stintzing S, et al. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). Ann Oncol 2020; 31:72.</a></li><li><a class="nounderline abstract_t">Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006; 8 Suppl 1:S7.</a></li><li><a class="nounderline abstract_t">Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13:3913.</a></li><li><a class="nounderline abstract_t">Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235.</a></li><li><a class="nounderline abstract_t">Tougeron D, Emambux S, Favot L, et al. Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). Oncoimmunology 2020; 9:1848058.</a></li><li><a class="nounderline abstract_t">Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012; 78:8.</a></li><li><a class="nounderline abstract_t">Wei F, Shin D, Cai X. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. Int J Clin Oncol 2018; 23:443.</a></li><li><a class="nounderline abstract_t">Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 2013; 8:173.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012; 30:2861.</a></li><li><a class="nounderline abstract_t">Eilers RE Jr, Gandhi M, Patel JD, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010; 102:47.</a></li><li><a class="nounderline abstract_t">Li J, Peccerillo J, Kaley K, Saif MW. Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP 2009; 10:338.</a></li><li><a class="nounderline abstract_t">Grenader T, Gipps M, Goldberg A. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008; 9:59.</a></li><li><a class="nounderline abstract_t">Qi WX, Fu S, Zhang Q, Guo XM. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. BMC Med 2014; 12:203.</a></li><li><a class="nounderline abstract_t">Burtness B, Anadkat M, Basti S, et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009; 7 Suppl 1:S5.</a></li><li><a class="nounderline abstract_t">Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425.</a></li><li><a class="nounderline abstract_t">Rerknimitr P, Suphankong Y, Panchaprateep R, et al. Pulsed-dye laser as an adjuvant treatment for papulopustular eruptions from epidermal growth factor receptor inhibitors, a randomized blinded split-faced controlled trial. Lasers Surg Med 2019; 51:584.</a></li><li><a class="nounderline abstract_t">Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 2007; 21:34.</a></li><li><a class="nounderline abstract_t">Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 2012; 67:1025.</a></li><li class="breakAll">Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 28, 2018).</li><li><a class="nounderline abstract_t">Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007; 25:5121.</a></li><li><a class="nounderline abstract_t">Balagula Y, Garbe C, Myskowski PL, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011; 50:129.</a></li><li><a class="nounderline abstract_t">Du-Thanh A, Merlet S, Maillard H, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol 2011; 165:1337.</a></li><li><a class="nounderline abstract_t">Mahé E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol 2006; 55:139.</a></li><li><a class="nounderline abstract_t">Campistol JM, de Fijter JW, Flechner SM, et al. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 2010; 24:149.</a></li><li><a class="nounderline abstract_t">Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13:1001.</a></li><li><a class="nounderline abstract_t">Balagula Y, Barth Huston K, Busam KJ, et al. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011; 29:1114.</a></li><li><a class="nounderline abstract_t">Bachet JB, Peuvrel L, Bachmeyer C, et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 2012; 17:555.</a></li><li><a class="nounderline abstract_t">Petrelli F, Borgonovo K, Cabiddu M, et al. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol 2016; 175:1166.</a></li><li><a class="nounderline abstract_t">Antonetti P, Fargnoli MC, Porzio G, et al. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? Support Care Cancer 2022; 30:2455.</a></li><li><a class="nounderline abstract_t">Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25:5390.</a></li><li><a class="nounderline abstract_t">Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:1351.</a></li><li><a class="nounderline abstract_t">Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113:847.</a></li><li><a class="nounderline abstract_t">Deplanque G, Chavaillon J, Vergnenegre A. CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. J Clin Oncol 2010; 28:640s.</a></li><li><a class="nounderline abstract_t">Hofheinz RD, Lorenzen S, Trojan J, et al. EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Ann Oncol 2018; 29:1010.</a></li><li><a class="nounderline abstract_t">Belum VR, Marchetti MA, Dusza SW, et al. A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash. J Am Acad Dermatol 2017; 77:577.</a></li><li><a class="nounderline abstract_t">Shacham Shmueli E, Geva R, Yarom N, et al. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study. Support Care Cancer 2019; 27:3027.</a></li><li><a class="nounderline abstract_t">Kripp M, Prasnikar N, Vehling-Kaiser U, et al. AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer. Oncotarget 2017; 8:105061.</a></li><li><a class="nounderline abstract_t">Wollenberg A, Moosmann N, Klein E, Katzer K. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 2008; 17:790.</a></li><li><a class="nounderline abstract_t">Amitay-Laish I, Prag-Naveh H, Ollech A, et al. Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial. Dermatology 2021; 237:988.</a></li><li><a class="nounderline abstract_t">Boone SL, Rademaker A, Liu D, et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007; 72:152.</a></li><li><a class="nounderline abstract_t">Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer 2017; 25:651.</a></li><li><a class="nounderline abstract_t">Melosky B, Burkes R, Rayson D, et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009; 16:16.</a></li><li><a class="nounderline abstract_t">Potthoff K, Hofheinz R, Hassel JC, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011; 22:524.</a></li><li><a class="nounderline abstract_t">Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012; 13:1020.</a></li><li><a class="nounderline abstract_t">Mir O, Coriat R. Aprepitant for pruritus: drug-drug interactions matter. Lancet Oncol 2012; 13:964.</a></li><li><a class="nounderline abstract_t">Porzio G, Aielli F, Verna L, et al. Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage 2006; 32:397.</a></li><li><a class="nounderline abstract_t">Klesse LJ, Jordan JT, Radtke HB, et al. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. Oncologist 2020; 25:e1109.</a></li><li><a class="nounderline abstract_t">Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 19:1079.</a></li><li><a class="nounderline abstract_t">Requena C, Llombart B, Sanmartín O. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin. Cutis 2012; 90:77.</a></li><li><a class="nounderline abstract_t">Gerber PA, Meller S, Eames T, et al. Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. Eur J Med Res 2012; 17:4.</a></li><li><a class="nounderline abstract_t">DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007; 56:500.</a></li><li><a class="nounderline abstract_t">Gutzmer R, Werfel T, Mao R, et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005; 153:849.</a></li><li><a class="nounderline abstract_t">Caruana M, Hatami A, Marcoux D, et al. Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib. JAAD Case Rep 2020; 6:1056.</a></li><li><a class="nounderline abstract_t">Andrews ED, Garg N, Patel AB. A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitor- and mitogen-activated protein kinase kinase inhibitor-induced acneiform eruptions. J Am Acad Dermatol 2020; 82:998.</a></li><li><a class="nounderline abstract_t">Kim YS, Ji JH, Oh SY, et al. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities. Oncologist 2020; 25:e186.</a></li><li><a class="nounderline abstract_t">Hwang IG, Kang JH, Oh SY, et al. Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Support Care Cancer 2016; 24:301.</a></li><li><a class="nounderline abstract_t">Lacouture ME, Wainberg ZA, Patel AB, et al. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy. Cancer Discov 2021; 11:2158.</a></li><li><a class="nounderline abstract_t">Bavetta M, Silvaggio D, Campione E, et al. The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions. J Clin Med 2021; 10.</a></li></ol></div><div id="topicVersionRevision">Topic 15764 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24313958" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22805291" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24840079" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The clinical development of MEK inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18988655" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15851793" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28152546" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33248228" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18467727" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19622902" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21402620" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27796680" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21689147" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34145608" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20798191" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16609030" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effects of smoking on the pharmacokinetics of erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19164205" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990857" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mechanisms of cutaneous toxicities to EGFR inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1693937" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immunolocalization of epidermal growth factor receptors in normal developing human skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6092481" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860957" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903175" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773160" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12409327" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9044042" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : EGF-R dependent regulation of keratinocyte survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15205458" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23966300" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Epidermal EGFR controls cutaneous host defense and prevents inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20621734" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422037" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23966299" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7489711" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19584274" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31826981" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31805013" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : IL-36γdrives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20709888" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10911738" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : UVB-induced epidermal growth factor receptor phosphorylation is critical for downstream signaling and keratinocyte survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17010747" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23941617" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12855621" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20732960" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908348" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17141360" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564072" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15270903" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19258241" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17522250" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31803963" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993230" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11432895" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19452131" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Skin toxicities associated with epidermal growth factor receptor inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15269313" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23067213" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22644776" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31912799" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17239291" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606725" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051966" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33299659" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22795701" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29289981" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23321777" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22753904" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20007525" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19454833" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18282360" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25369798" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470276" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16012181" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30843231" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pulsed-dye laser as an adjuvant treatment for papulopustular eruptions from epidermal growth factor receptor inhibitors, a randomized blinded split-faced controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18154217" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22502948" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22502948" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17991931" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Patient-reported outcomes and the evolution of adverse event reporting in oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21244375" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21777222" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16781309" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20236129" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : mTOR inhibitor-associated dermatologic and mucosal problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779536" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20978926" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22426526" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27214209" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34779921" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18048820" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142600" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18543329" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29360920" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28807114" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30607677" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29285233" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18503553" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33378750" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18160805" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27718067" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19229368" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20709812" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22995650" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22995652" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Aprepitant for pruritus: drug-drug interactions matter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085262" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Efficacy of pregabalin in the management of cetuximab-related itch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32272491" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21630130" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22988651" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22472354" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166623" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16181478" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32995446" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31604105" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitor- and mitogen-activated protein kinase kinase inhibitor-induced acneiform eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31492766" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26041481" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33910927" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33530427" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
